midodrine has been researched along with Ascites in 30 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventy-five patients with cirrhosis and refractory ascites were randomized to receive albumin infusion, oral midodrine for 2 days, or oral midodrine for 30 days after therapeutic large volume paracentesis (LVP)." | 9.30 | Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. ( Eletreby, R; Elkady, MA; Hamza, I; Ismail, A; Soliman, ZA; Yosry, A, 2019) |
| "Fifty cirrhotic patients with refractory or recurrent ascites were randomised to receive midodrine (n=13), tolvaptan (n=12) or both (n=13) plus standard medical therapy (SMT) or SMT alone (n=12)." | 9.24 | Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. ( Bhalla, A; Rai, N; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2017) |
| "Adding rifaximin and midodrine to DT enhanced diuresis in refractory ascites with improved systemic, renal hemodynamics and short-term survival." | 9.22 | Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. ( Hanafy, AS; Hassaneen, AM, 2016) |
| "Midodrine appeared to be effective in lowering body weights and abdominal girths of non azotemic cirrhotic patients with tense ascites." | 9.19 | Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. ( Al-Garem, N; Ali, A; Amin, M; Farid, S; Kassem, M, 2014) |
| "Sixty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long-term administration of clonidine (n=15) or midodrine (n=15), or both (n=15) plus standard medical therapy (SMT), or SMT alone (n=15), in a randomized controlled trial at a tertiary center." | 9.17 | Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Ghai, A; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2013) |
| "The results of this randomized pilot study suggest that midodrine plus standard medical therapy improves the systemic hemodynamics without any renal or hepatic dysfunction in these patients and is superior to standard medical therapy alone for the control of ascites." | 9.16 | Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Dhungana, SP; Gupta, PK; Nain, CK; Sharma, N; Singh, B; Singh, V; Vijayverghia, R, 2012) |
| "We performed a multicenter, randomized, double-blind, placebo-controlled trial to compare albumin with the vasoconstrictor combination of octreotide and midodrine in patients with refractory ascites who underwent LVP." | 9.16 | The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. ( Bari, K; Garcia-Tsao, G; Gilles, H; Hashem, HJ; Heuman, D; Inayat, IB; Miñano, C; Shea, M, 2012) |
| "Oral midodrine does not increase the natriuretic response to furosemide in non-azotemic cirrhotic patients with ascites." | 9.14 | The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. ( Chalasani, N; Hamman, M; Jones, D; Kahi, C; Kwo, PY; Misra, VL; Vuppalanchi, R, 2010) |
| " Midodrine has shown promising results in the treatment of AKI-hepatorenal syndrome (HRS-AKI)." | 8.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "Pharmacokinetic parameters of midodrine can differ significantly in cirrhotic patients with tense ascites from those in healthy individuals." | 7.83 | Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers. ( Al-Garem, N; Al-Ghobashy, M; Ali, A; Amin, M; Farid, S; Kassem, M, 2016) |
| " In conclusion, the long-term administration of midodrine and octreotide seems to be an effective and safe treatment of type 1 HRS in patients with cirrhosis." | 6.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| "Seventy-five patients with cirrhosis and refractory ascites were randomized to receive albumin infusion, oral midodrine for 2 days, or oral midodrine for 30 days after therapeutic large volume paracentesis (LVP)." | 5.30 | Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. ( Eletreby, R; Elkady, MA; Hamza, I; Ismail, A; Soliman, ZA; Yosry, A, 2019) |
| "Fifty cirrhotic patients with refractory or recurrent ascites were randomised to receive midodrine (n=13), tolvaptan (n=12) or both (n=13) plus standard medical therapy (SMT) or SMT alone (n=12)." | 5.24 | Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. ( Bhalla, A; Rai, N; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2017) |
| "Adding rifaximin and midodrine to DT enhanced diuresis in refractory ascites with improved systemic, renal hemodynamics and short-term survival." | 5.22 | Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. ( Hanafy, AS; Hassaneen, AM, 2016) |
| "This pilot study suggests that midodrine is not as effective as intravenous albumin in preventing circulatory dysfunction after large-volume paracentesis in patients with cirrhosis and tense ascites, especially with HCC-positive patients." | 5.19 | Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. ( ElBaz, AA; Hamdy, H; Hassan, A; Hassanin, O, 2014) |
| "Midodrine appeared to be effective in lowering body weights and abdominal girths of non azotemic cirrhotic patients with tense ascites." | 5.19 | Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. ( Al-Garem, N; Ali, A; Amin, M; Farid, S; Kassem, M, 2014) |
| "Sixty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long-term administration of clonidine (n=15) or midodrine (n=15), or both (n=15) plus standard medical therapy (SMT), or SMT alone (n=15), in a randomized controlled trial at a tertiary center." | 5.17 | Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Ghai, A; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2013) |
| "The results of this randomized pilot study suggest that midodrine plus standard medical therapy improves the systemic hemodynamics without any renal or hepatic dysfunction in these patients and is superior to standard medical therapy alone for the control of ascites." | 5.16 | Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Dhungana, SP; Gupta, PK; Nain, CK; Sharma, N; Singh, B; Singh, V; Vijayverghia, R, 2012) |
| "Oral midodrine does not increase the natriuretic response to furosemide in non-azotemic cirrhotic patients with ascites." | 5.14 | The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. ( Chalasani, N; Hamman, M; Jones, D; Kahi, C; Kwo, PY; Misra, VL; Vuppalanchi, R, 2010) |
| "This pilot study suggests that midodrine is not as effective as albumin in preventing circulatory dysfunction after large-volume paracentesis in patients with cirrhosis and ascites." | 5.13 | Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. ( Appenrodt, B; Grünhage, F; Heller, J; Lammert, F; Rabe, C; Sauerbruch, T; Schepke, M; Trebicka, J; Wolf, A, 2008) |
| "To review studies evaluating the use of midodrine and octreotide in hemodynamic complications of cirrhosis, including ascites and hepatorenal syndrome." | 4.85 | Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. ( Karwa, R; Woodis, CB, 2009) |
| " Midodrine has shown promising results in the treatment of AKI-hepatorenal syndrome (HRS-AKI)." | 4.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "Pharmacokinetic parameters of midodrine can differ significantly in cirrhotic patients with tense ascites from those in healthy individuals." | 3.83 | Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers. ( Al-Garem, N; Al-Ghobashy, M; Ali, A; Amin, M; Farid, S; Kassem, M, 2016) |
| "Treatment with midodrine and albumin was associated with a slight but significant decrease in plasma renin activity and aldosterone compared to placebo (renin -4." | 2.87 | Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. ( Ariza, X; Castellote, J; Colmenero, J; Córdoba, J; de Prada, G; Fabrellas, N; Garcia-Martínez, R; Ginès, P; Graupera, I; Guevara, M; Huelin, P; Lopez Benaiges, E; Manríquez, M; Márquez, F; Martín-Llahí, M; Moreira, R; Navasa, M; Nazar, A; Pavesi, M; Pose, E; Simón-Talero, M; Solà, E; Solé, C; Suñé, P; Torrens, M; Vargas, V; Ventura, M; Xiol, X, 2018) |
| "Midodrine therapy was cheaper than albumin therapy." | 2.73 | Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. ( Bhalla, A; Chawla, D; Dheerendra, PC; Mahi, SK; Nain, CK; Sharma, N; Singh, B; Singh, V, 2008) |
| " In conclusion, the long-term administration of midodrine and octreotide seems to be an effective and safe treatment of type 1 HRS in patients with cirrhosis." | 2.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| "The hepatorenal syndrome is a well-recognized complication of advanced cirrhosis and is usually associated with an accelerated course to death unless liver transplantation is performed." | 2.53 | Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. ( Bertino, G; Crisafulli, E; Demma, S; Koukias, N; Privitera, G; Purrello, F; Spadaro, L; Tsochatzis, EA, 2016) |
| "Midodrine (MD) is a prodrug that is converted after oral administration to Desglymidodrine (DMD)." | 1.42 | Development and validation of LC-MS/MS assay for the determination of the prodrug Midodrine and its active metabolite Desglymidodrine in plasma of ascitic patients: Application to individualized therapy and comparative pharmacokinetics. ( Al-Ghobashy, MA; Ali, AA; Farid, SF; Kassem, MA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marigliano, B | 1 |
| Internullo, M | 1 |
| Scuro, L | 1 |
| Tavanti, A | 1 |
| Del Vecchio, LR | 1 |
| Schito, MB | 1 |
| Colombo, GM | 1 |
| Guglielmelli, E | 1 |
| Tripathy, A | 1 |
| Maiti, R | 1 |
| Jena, M | 1 |
| Mishra, A | 1 |
| Srinivasan, A | 1 |
| Sharma, P | 1 |
| Puri, P | 1 |
| Bansal, N | 1 |
| Singla, V | 1 |
| Kumar, A | 1 |
| ShriHari, AA | 1 |
| Arora, A | 1 |
| Solà, E | 1 |
| Solé, C | 1 |
| Simón-Talero, M | 1 |
| Martín-Llahí, M | 1 |
| Castellote, J | 1 |
| Garcia-Martínez, R | 1 |
| Moreira, R | 1 |
| Torrens, M | 1 |
| Márquez, F | 1 |
| Fabrellas, N | 1 |
| de Prada, G | 1 |
| Huelin, P | 1 |
| Lopez Benaiges, E | 1 |
| Ventura, M | 1 |
| Manríquez, M | 1 |
| Nazar, A | 1 |
| Ariza, X | 1 |
| Suñé, P | 1 |
| Graupera, I | 1 |
| Pose, E | 1 |
| Colmenero, J | 1 |
| Pavesi, M | 1 |
| Guevara, M | 1 |
| Navasa, M | 1 |
| Xiol, X | 1 |
| Córdoba, J | 1 |
| Vargas, V | 1 |
| Ginès, P | 1 |
| Yosry, A | 1 |
| Soliman, ZA | 1 |
| Eletreby, R | 1 |
| Hamza, I | 1 |
| Ismail, A | 1 |
| Elkady, MA | 1 |
| Singh, V | 4 |
| Singh, A | 2 |
| Singh, B | 4 |
| Vijayvergiya, R | 2 |
| Sharma, N | 4 |
| Ghai, A | 1 |
| Bhalla, A | 4 |
| Hsu, SJ | 1 |
| Huang, HC | 1 |
| Hamdy, H | 1 |
| ElBaz, AA | 2 |
| Hassan, A | 1 |
| Hassanin, O | 1 |
| Bai, M | 1 |
| Han, G | 1 |
| Ali, A | 2 |
| Farid, S | 2 |
| Amin, M | 2 |
| Kassem, M | 2 |
| Al-Garem, N | 2 |
| Ali, AA | 1 |
| Al-Ghobashy, MA | 1 |
| Farid, SF | 1 |
| Kassem, MA | 1 |
| Sansoè, G | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Parola, M | 1 |
| Al-Ghobashy, M | 1 |
| Bertino, G | 1 |
| Privitera, G | 1 |
| Purrello, F | 1 |
| Demma, S | 1 |
| Crisafulli, E | 1 |
| Spadaro, L | 1 |
| Koukias, N | 1 |
| Tsochatzis, EA | 1 |
| Rai, N | 1 |
| Hanafy, AS | 1 |
| Hassaneen, AM | 1 |
| Dheerendra, PC | 1 |
| Nain, CK | 2 |
| Chawla, D | 1 |
| Mahi, SK | 1 |
| Kalambokis, GN | 1 |
| Tsianos, EV | 3 |
| Karwa, R | 1 |
| Woodis, CB | 1 |
| Misra, VL | 1 |
| Vuppalanchi, R | 1 |
| Jones, D | 1 |
| Hamman, M | 1 |
| Kwo, PY | 1 |
| Kahi, C | 1 |
| Chalasani, N | 1 |
| Kalambokis, G | 2 |
| Dhungana, SP | 1 |
| Vijayverghia, R | 1 |
| Gupta, PK | 1 |
| Bari, K | 1 |
| Miñano, C | 1 |
| Shea, M | 1 |
| Inayat, IB | 1 |
| Hashem, HJ | 1 |
| Gilles, H | 1 |
| Heuman, D | 1 |
| Garcia-Tsao, G | 1 |
| Wong, F | 1 |
| Pantea, L | 1 |
| Sniderman, K | 1 |
| Fotopoulos, A | 1 |
| Economou, M | 1 |
| Appenrodt, B | 1 |
| Wolf, A | 1 |
| Grünhage, F | 1 |
| Trebicka, J | 1 |
| Schepke, M | 1 |
| Rabe, C | 1 |
| Lammert, F | 1 |
| Sauerbruch, T | 1 |
| Heller, J | 1 |
| Tandon, P | 1 |
| Tsuyuki, RT | 1 |
| Mitchell, L | 1 |
| Hoskinson, M | 1 |
| Ma, MM | 1 |
| Wong, WW | 1 |
| Mason, AL | 1 |
| Gutfreund, K | 1 |
| Bain, VG | 1 |
| Angeli, P | 2 |
| Volpin, R | 2 |
| Piovan, D | 1 |
| Bortoluzzi, A | 1 |
| Craighero, R | 2 |
| Bottaro, S | 1 |
| Finucci, GF | 1 |
| Casiglia, E | 1 |
| Sticca, A | 2 |
| De Toni, R | 1 |
| Pavan, L | 1 |
| Gatta, A | 2 |
| Gerunda, G | 1 |
| Roner, P | 1 |
| Merenda, R | 1 |
| Amodio, P | 1 |
| Caregaro, L | 1 |
| Maffei-Faccioli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation[NCT00839358] | Phase 4 | 199 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Midodrine Versus Albumin During Large-volume Paracentesis and Its Effect on Paracentesis Induced Circulatory Disturbance in Patients With Acute on Chronic Liver Failure - A Randomized Controlled Trial[NCT05240391] | Phase 3 | 50 participants (Actual) | Interventional | 2021-02-20 | Completed | ||
| Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites[NCT02173288] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children: a Pilot Study[NCT04043858] | 20 participants (Anticipated) | Interventional | 2020-06-05 | Recruiting | |||
| Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355] | Phase 4 | 29 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Egyptian Cirrhotic Patients With Ascites[NCT04785755] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-30 | Completed | ||
| Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study[NCT00986817] | Phase 3 | 82 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis
| Intervention | participants (Number) |
|---|---|
| Albumin (Control Group) | 2 |
| Vasoconstrictor (Treatment Group) | 2 |
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days
| Intervention | days (Median) |
|---|---|
| Albumin (Control Group) | 10 |
| Vasoconstrictor (Treatment Group) | 8 |
4 reviews available for midodrine and Ascites
| Article | Year |
|---|---|
Effect of alpha agonists on the prevention of postparacentesis circulatory dysfunction in patients with refractory or recurrent ascites: a meta-analysis.
Topics: Aldosterone; Ascites; Humans; Midodrine; Shock | 2020 |
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, T | 2013 |
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
Topics: Acute Kidney Injury; Adrenal Insufficiency; Ascites; Creatinine; Evidence-Based Medicine; Hepatorena | 2016 |
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Topics: Ascites; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octreotide; Treatme | 2009 |
14 trials available for midodrine and Ascites
| Article | Year |
|---|---|
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
Topics: Adult; Aged; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2018 |
Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Albumins; Ascites; Cost-Benefit A | 2019 |
Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Ascites; Cl | 2013 |
Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
Topics: Albumins; Aldosterone; Ascites; Creatinine; Female; Humans; Hypovolemia; Liver Cirrhosis; Male; Midd | 2014 |
Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Ascites; Blood Flow Velocity; Double-Blind Method; Drain | 2014 |
Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.
Topics: Adult; Ascites; Benzazepines; Drug Therapy, Combination; Female; Humans; India; Liver Cirrhosis; Mal | 2017 |
Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
Topics: Aldosterone; Anti-Infective Agents; Ascites; Blood Pressure; Body Weight; Diuretics; Drug Therapy, C | 2016 |
Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.
Topics: Adult; Ascites; Female; Humans; Hypovolemia; Liver Cirrhosis; Male; Middle Aged; Midodrine; Paracent | 2008 |
The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.
Topics: Administration, Oral; Ascites; Creatinine; Cross-Over Studies; Diuretics; Double-Blind Method; Femal | 2010 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ascites; Double-Blind Method; Female; Humans; Male; Midd | 2012 |
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Blood Volume; Creatinine; Drug Therapy, C | 2004 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Topics: Aldosterone; Ascites; Blood Pressure; Diuresis; Electrolytes; Gastrointestinal Agents; Glomerular Fi | 1999 |
12 other studies available for midodrine and Ascites
| Article | Year |
|---|---|
Midodrine and albumin as a possible "winning pair" in managing paracentesis-induced circulatory dysfunction: a clinical case report.
Topics: Albumins; Ascites; Diuretics; Female; Heart Failure; Humans; Liver Cirrhosis; Middle Aged; Midodrine | 2022 |
Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
Topics: Acute Kidney Injury; Albumins; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Pi | 2021 |
Midodrine for paracentesis-induced circulatory dysfunction.
Topics: Albumins; Ascites; Female; Humans; Hypovolemia; Male; Midodrine; Paracentesis; Vasoconstrictor Agent | 2014 |
In response.
Topics: Albumins; Ascites; Female; Humans; Hypovolemia; Male; Midodrine; Paracentesis; Vasoconstrictor Agent | 2014 |
Development and validation of LC-MS/MS assay for the determination of the prodrug Midodrine and its active metabolite Desglymidodrine in plasma of ascitic patients: Application to individualized therapy and comparative pharmacokinetics.
Topics: Adrenergic alpha-1 Receptor Agonists; Ascites; Chromatography, High Pressure Liquid; Drug Monitoring | 2015 |
Dose-dependency of clonidine's effects in ascitic cirrhotic rats: comparison with α1-adrenergic agonist midodrine.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Animals; Ascites; Blood | 2016 |
Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers.
Topics: Adrenergic alpha-Agonists; Adult; Ascites; Case-Control Studies; Female; Humans; Liver Cirrhosis; Ma | 2016 |
Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodr | 2008 |
Midodrine and furosemide-induced natriuresis in cirrhotics with ascites.
Topics: Ascites; Furosemide; Humans; Liver Cirrhosis; Midodrine; Natriuresis | 2011 |
Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.
Topics: Adrenergic alpha-Agonists; Aged; Ascites; Drug Therapy, Combination; Female; Gastrointestinal Agents | 2005 |
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
Topics: Alberta; Albumins; Aldosterone; Analysis of Variance; Ascites; Creatine; Female; Humans; Male; Metab | 2009 |
Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Ascites; Blood Pressure; Cardiac Output; Female; Gl | 1998 |